Mike Hollan

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing drug prices.

The federally created panel was previously disbanded in 1998.

The new list price will bring the medication in line with other European markets.

Sources say the President’s focus has shifted.

Users find themselves suddenly looking for an extra $500-a-month in their budgets.

Attorney General Paxton argues that the company’s programs and offerings were essentially bribes and resulted in millions in dollars charged to the state’s Medicaid program.

The specialty medication platform earned a spot in the top 15% of the list.

The urology MSO will become part of The Specialty Alliance.

The journal is standing by the study, which looked into the safety of vaccines that have aluminum ingredients.

Secretary Kennedy explained that nearly $500 million in contracts will be canceled.

The talks are a result of the MFN order, which seeks to make US drug prices match lower prices in international markets.

With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?

The industry is facing calls to reduce prices while also bracing for increased tariffs.

The move comes amidst a turbulent time at HHS.

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.

Members of the industry believe the US should remain an innovation-friendly market.

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

The actor was diagnosed with the disease at 46-years-old.

The letter states that the companies have 60 days to meet the President's requirements.

Gen Li discusses when the industry can expect to start seeing technological advancements implemented.

The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the medication themselves.

The gene therapy will resume shipments for patients who are ambulatory.

The restructuring includes the elimination of certain roles and a reduction in the company’s global real estate footprint.

The Anywhere platform will be available to a wider network of providers and patients.

Gen Li discusses the current state of technological advancement in clinical trials.

The project will provide about 300,000 new square-feet of manufacturing space.

New technology has the potential to improve trial design and patient recruitment.

Dr. Zeskind discusses how Immuneering’s treatments can impact a broad range of cancer types.

A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at FDA’s CBER, and how industry can navigate the path forward.